To the full analysis
Agilent Technologies stock: growth
AAgilent Technologies reported $6.95B in revenue for fiscal 2025, up 6.7% on the prior year, up 5.4% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
1.8%
per year from 2006 to 2025, per share 4.1%
Earnings (Annual rate)
−4.8%
per year from 2006 to 2025, per share −2.7%
Free cash flow (Annual rate)
5.1%
per year from 2006 to 2025, per share 7.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.4% | 5.6% | 1.8% |
| Revenue per share | 7.3% | 7.3% | 4.1% |
| Earnings | 12.6% | 12.5% | −4.8% |
| Earnings per share | 14.5% | 14.4% | −2.7% |
| Free cash flow | 7.5% | 11.4% | 5.1% |
| Free cash flow per share | 9.4% | 13.2% | 7.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $4.97B | $3.31B | $449M |
| 2007 | $5.42B | $638M | $815M |
| 2008 | $5.77B | $693M | $602M |
| 2009 | $4.48B | −$31M | $280M |
| 2010 | $5.44B | $684M | $593M |
| 2011 | $6.62B | $1.01B | $1.07B |
| 2012 | $6.86B | $1.15B | $1.04B |
| 2013 | $3.89B | $724M | $957M |
| 2014 | $4.05B | $549M | $506M |
| 2015 | $4.04B | $401M | $393M |
| 2016 | $4.2B | $460M | $654M |
| 2017 | $4.47B | $684M | $713M |
| 2018 | $4.91B | $316M | $910M |
| 2019 | $5.16B | $1.07B | $865M |
| 2020 | $5.34B | $719M | $802M |
| 2021 | $6.32B | $1.21B | $1.3B |
| 2022 | $6.85B | $1.25B | $1.02B |
| 2023 | $6.83B | $1.24B | $1.47B |
| 2024 | $6.51B | $1.29B | $1.37B |
| 2025 | $6.95B | $1.3B | $1.15B |
Revenue by segment
How Agilent Technologies, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Agilent CrossLab$2.9B42%
- Life Sciences and Applied Markets$2.7B39%
- Applied Markets$1.3B19%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Agilent CrossLab | $2.91B | 41.9% |
| Life Sciences and Applied Markets | $2.73B | 39.2% |
| Applied Markets | $1.31B | 18.9% |
| Total revenue | $6.95B | 100% |
Revenue by region
Where Agilent Technologies, Inc. generates its revenue.
- Americas40%
- Asia Pacific32%
- Europe28%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| Americas | $1.86B | $1.97B | $2.4B | $2.68B | $2.73B | $2.57B | $2.81B | 40.4% |
| Asia Pacific | $1.86B | $1.93B | $2.23B | $2.47B | $2.35B | $2.17B | $2.22B | 31.9% |
| Europe | $1.44B | $1.44B | $1.69B | $1.7B | $1.75B | $1.77B | $1.92B | 27.7% |
| Total revenue | $5.16B | $5.34B | $6.32B | $6.85B | $6.83B | $6.51B | $6.95B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Oct 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.